Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1, 048 patients hospitalised during the 2016-17 and 2017-18  influenza seasons. Issue 3 (March 2023)

• Record Type: Journal Article
• Authors: Reacher, Mark; Warne, Ben; Verlander, Neville Q.; Popay, Ashley; Reeve, Lucy; Jones, Nicholas K.; Ranellou, Kyriaki; Sithole, Nyaradzai; Carpenter, Rory; Everden, Angharad; Jarman, Elizabeth; Khalid, Ali; Lam, Kyle; Myers, Chloe; Ren, Shuhui; Rolfe, Kathryn J; Sutton, Tommy; Christou, Silvana; Wright, Callum; Choudhry, Saher; Zambon, Maria; Sander, Clare; Zhang, Hongyi; Jalal, Hamid
• Is Part Of: Journal of infection. Volume 86:Issue 3(2023)
• Page Start: 256
• Page End: 308
• Publication Date: 2023-03
• Subjects: Historic Cohort study -- Influenza B -- Influenza A (H3N2) in-patient mortality -- PCR -- Multiplex PCR -- Logistic regression -- Multivariable logistic regression; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2023.01.004
• Languages: English
• ISSNs: 0163-4453

Abstract

Abstract: Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07, 0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.